{"id":65994,"date":"2026-05-22T21:26:30","date_gmt":"2026-05-22T13:26:30","guid":{"rendered":"https:\/\/flcube.com\/?p=65994"},"modified":"2026-05-22T21:26:31","modified_gmt":"2026-05-22T13:26:31","slug":"bayers-kerendia-receives-fda-priority-review-for-expanded-indication-in-type-1-diabetes-associated-chronic-kidney-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65994","title":{"rendered":"Bayer&#8217;s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bayer AG (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>)<\/strong> announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted for review with <strong>priority review status<\/strong> a <strong>supplementary New Drug Application (sNDA)<\/strong> for <strong>Kerendia (finerenone)<\/strong>, a <strong>mineralocorticoid receptor (MR) antagonist<\/strong>. The targeted indication is <strong>chronic kidney disease (CKD) associated with type 1 diabetes (T1D)<\/strong>, potentially expanding access to this therapy for a significant patient population currently without approved treatment options.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Applicant<\/strong><\/td><td>Bayer AG (ETR: BAYN)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Kerendia (finerenone) \u2013 mineralocorticoid receptor antagonist<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplementary New Drug Application (sNDA)<\/td><\/tr><tr><td><strong>Review Designation<\/strong><\/td><td>Priority Review<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Chronic kidney disease (CKD) associated with type 1 diabetes (T1D)<\/td><\/tr><tr><td><strong>Current FDA Approvals<\/strong><\/td><td>CKD associated with type 2 diabetes; heart failure with LVEF \u2265 40%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-base\" class=\"wp-block-heading\">Clinical Evidence Base<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Supporting Study:<\/strong> Phase III FINE-ONE trial<\/li>\n\n\n\n<li><strong>Population:<\/strong> Adults with T1D and CKD<\/li>\n\n\n\n<li><strong>Intervention:<\/strong> Kerendia added to standard of care vs. placebo<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Urinary albumin-to-creatinine ratio (UACR) reduction at 6 months<\/li>\n\n\n\n<li><strong>Result:<\/strong> Statistically significant UACR reduction compared to placebo<\/li>\n\n\n\n<li><strong>Additional Supporting Data:<\/strong> Pooled analysis from Phase III FIDELIO-DKD and FIGARO-DKD trials<\/li>\n\n\n\n<li><strong>Population:<\/strong> Adult patients with CKD associated with type 2 diabetes (T2D)<\/li>\n\n\n\n<li><strong>Relevance:<\/strong> Demonstrates consistent efficacy and safety profile across diabetes types<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-assessment\" class=\"wp-block-heading\">Market Opportunity Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Addressable Population<\/strong><\/td><td>Estimated 1.6 million adults with T1D and CKD in the U.S.<\/td><\/tr><tr><td><strong>Current Treatment Gap<\/strong><\/td><td>No FDA-approved therapies specifically indicated for T1D-associated CKD<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>First-in-class MR antagonist with potential dual approval for both T1D and T2D-associated CKD<\/td><\/tr><tr><td><strong>Revenue Impact<\/strong><\/td><td>Potential to expand Kerendia&#8217;s U.S. market by 25\u201330% if approved<\/td><\/tr><tr><td><strong>Pricing Strategy<\/strong><\/td><td>Likely consistent with current T2D indication pricing (~$1,200\/month)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The priority review designation, which shortens the FDA review timeline from 10 months to 6 months, reflects the significant unmet medical need in T1D-associated CKD, where patients face progressive kidney function decline and increased cardiovascular risk.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications-amp-forward-outlook\" class=\"wp-block-heading\">Strategic Implications &amp; Forward Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Expansion:<\/strong> Successful approval would make Kerendia the first and only therapy approved for both T1D and T2D-associated CKD<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> MR antagonism represents a novel mechanism distinct from SGLT2 inhibitors and RAS blockers currently used off-label<\/li>\n\n\n\n<li><strong>Global Regulatory Strategy:<\/strong> U.S. approval could facilitate similar submissions to EMA and other international regulatory bodies<\/li>\n\n\n\n<li><strong>Commercial Readiness:<\/strong> Bayer&#8217;s established nephrology sales force can immediately support expanded indication launch<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Strengthens Bayer&#8217;s cardiorenal portfolio alongside existing heart failure and T2D-CKD indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory review timelines, market opportunities, and commercial expectations for Kerendia. Actual results may differ due to risks including FDA review outcomes, competitive dynamics, reimbursement decisions, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,69,967,38],"class_list":["post-65994","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bayer","tag-cvd","tag-etr-bayn","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer&#039;s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review with priority review status a supplementary New Drug Application (sNDA) for Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The targeted indication is chronic kidney disease (CKD) associated with type 1 diabetes (T1D), potentially expanding access to this therapy for a significant patient population currently without approved treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65994\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer&#039;s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review with priority review status a supplementary New Drug Application (sNDA) for Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The targeted indication is chronic kidney disease (CKD) associated with type 1 diabetes (T1D), potentially expanding access to this therapy for a significant patient population currently without approved treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65994\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T13:26:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-22T13:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65994#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65994\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer&#8217;s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease\",\"datePublished\":\"2026-05-22T13:26:30+00:00\",\"dateModified\":\"2026-05-22T13:26:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65994\"},\"wordCount\":456,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bayer\",\"CVD\",\"ETR: BAYN\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65994#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65994\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65994\",\"name\":\"Bayer's Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-22T13:26:30+00:00\",\"dateModified\":\"2026-05-22T13:26:31+00:00\",\"description\":\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review with priority review status a supplementary New Drug Application (sNDA) for Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The targeted indication is chronic kidney disease (CKD) associated with type 1 diabetes (T1D), potentially expanding access to this therapy for a significant patient population currently without approved treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65994#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65994\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65994#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer&#8217;s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review with priority review status a supplementary New Drug Application (sNDA) for Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The targeted indication is chronic kidney disease (CKD) associated with type 1 diabetes (T1D), potentially expanding access to this therapy for a significant patient population currently without approved treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65994","og_locale":"en_US","og_type":"article","og_title":"Bayer's Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease","og_description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review with priority review status a supplementary New Drug Application (sNDA) for Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The targeted indication is chronic kidney disease (CKD) associated with type 1 diabetes (T1D), potentially expanding access to this therapy for a significant patient population currently without approved treatment options.","og_url":"https:\/\/flcube.com\/?p=65994","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-22T13:26:30+00:00","article_modified_time":"2026-05-22T13:26:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65994#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65994"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer&#8217;s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease","datePublished":"2026-05-22T13:26:30+00:00","dateModified":"2026-05-22T13:26:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65994"},"wordCount":456,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bayer","CVD","ETR: BAYN","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65994#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65994","url":"https:\/\/flcube.com\/?p=65994","name":"Bayer's Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-22T13:26:30+00:00","dateModified":"2026-05-22T13:26:31+00:00","description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review with priority review status a supplementary New Drug Application (sNDA) for Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The targeted indication is chronic kidney disease (CKD) associated with type 1 diabetes (T1D), potentially expanding access to this therapy for a significant patient population currently without approved treatment options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65994#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65994"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65994#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer&#8217;s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65994"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65994\/revisions"}],"predecessor-version":[{"id":65996,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65994\/revisions\/65996"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}